Neil D. Gross, MD, FACS

Neil D. Gross, MD, FACS, discusses the heterogeneous nature of advanced CSCC.

Neil D. Gross, MD, FACS, discusses the importance of year-round vigilance when it comes to skin cancer prevention and education.

Panelists discuss strategies for integrating dermatology, surgery, radiation, and oncology to deliver cohesive, patient-centered cSCC care.

Panelists discuss strategies for long-term surveillance and management of patients with cSCC who have received adjuvant immunotherapy.

Panelists discuss ongoing clinical trials evaluating adjuvant immunotherapy for cSCC and the implications of early outcomes for clinical practice.

Panelists discuss how clinicians identify which patients are most likely to benefit from adjuvant immunotherapy based on clinical and pathologic risk factors.

Panelists discuss ongoing clinical trials, including adjuvant immunotherapy studies, and identify which patients are most likely to benefit from these strategies.

Panelists discuss the growing use of systemic immunotherapy for advanced or unresectable cSCC and how it integrates with other modalities.

Panelists discuss when radiation therapy is appropriate for treating cSCC, and how it complements surgical management.

Panelists discuss how to identify appropriate surgical candidates and coordinate timely referral to specialized surgical teams.

Panelists discuss standard primary treatment modalities for cSCC, emphasizing surgical control and selective use of adjunctive therapy.

Panelists discuss patient populations requiring earlier biopsy and aggressive workup to detect high-risk cSCC.

Panelists discuss the importance of following evidence-based clinical pathways and national guidelines to streamline cSCC care.

Panelists discuss when cSCC can be managed within dermatology and when multidisciplinary referral is warranted.

Panelists discuss how dermatologists serve as the first line of detection and play an essential role in early management and triage of cSCC.

Panelists discuss best practices for evaluating suspected cSCC, including lesion assessment, biopsy strategies, and initial patient workup.

Panelists discuss clinical and pathological factors used to stratify cSCC into low-, high-, and very high-risk categories.

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses 1-year follow-up data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Neil D. Gross, MD, FACS, discusses the prognosis of patients who are diagnosed with cutaneous squamous cell carcinoma of the head and neck.

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.